ATLANTA, July 08, 2025 (GLOBE NEWSWIRE) -- Gray Media, Inc. (“Gray,” “we,” “us,” or “our”) (NYSE: GTN) today announced an update to its financial guidance for the quarter ended June 30, 2025, along with certain other developments that occurred during the quarter. Updated Guidance for the Quarter Ended June 30, 2025 We have not completed the process to finalize our financial results for the quarter ended June 30, 2025. Nevertheless, based upon our current forecasts and internal estimates for the quarter, we ...

INVESTING IN LIFE'S ENDURING EXPERIENCES Q4 & YEAR END 2018 EARNINGS CALL FEBRUARY 26, 2019 PR Properties® Return on Insight INTRODUCTORY COMMENTS This information is as of the date indicated and, to our knowledge, was timely and accurate when presented. We are under no obligation to update or remove outdated information other than as required by applicable law or regulation. HEADLINES Strong Fourth Quarter Caps a Successful Year 1. R Properties® 3 HEADLINES Properties" 4 Strong Fourth Quarter Caps a Succes ...

Core Insights - Post Holdings, Inc. reported second-quarter fiscal 2025 results with net sales missing estimates but adjusted earnings exceeding expectations, both metrics showing year-over-year declines [1][2]. Financial Performance - Adjusted earnings per share were $1.41, surpassing the Zacks Consensus Estimate of $1.18, but down from $1.51 in the prior year [2]. - Net sales totaled $1,952.1 million, a 2.3% decrease year over year, missing the Zacks Consensus Estimate of $1,977 million [2]. - Gross profit was $545.8 million, down 5.8% year over year, with gross margin contracting to 28% from 29% [3]. - Selling, general and administrative expenses decreased by 7.8% to $314.8 million, representing 16.1% of net sales compared to 17.1% in the previous year [3]. - Operating profit decreased by 4.2% to $182.2 million, while adjusted EBITDA increased by 0.4% to $346.5 million [3]. Segment Performance - **Post Consumer Brands**: Net sales were $987.9 million, down 7.3% year over year, missing estimates. Volumes fell by 5.8%, with cereal volumes down 6.3% [4]. - **Weetabix**: Reported a 4.6% decline in net sales to $131.7 million, missing estimates. Volumes decreased by 7.1% [5]. - **Foodservice**: Achieved 9.6% growth in net sales to $607.9 million, surpassing estimates. Volumes grew by 2.8% [6]. - **Refrigerated Retail**: Sales dipped 6.6% to $224.6 million, missing estimates. Volumes dropped by 4.9% [7]. Other Financial Aspects - Cash and cash equivalents stood at $617.6 million, with long-term debt of $6,944.6 million and total shareholders' equity of $3,841.4 million [8]. - The company repurchased 1.7 million shares for $191.6 million in the second quarter, totaling 3.3 million shares for $372.7 million in the first half of fiscal 2025 [9][10]. Future Guidance - Post Holdings updated its fiscal 2025 adjusted EBITDA guidance to a range of $1,430-$1,470 million, up from the previous range of $1,420-$1,460 million [11]. - Expected capital expenditures for fiscal 2025 are between $390 million and $430 million, including significant investments in Post Consumer Brands and Foodservice [12].

Q1 2025 Earnings May 8, 2025 1 This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited. © 2025 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. Forward Looking Statements This presentation contains "forward-looking statements". These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of ...

Cencora, Inc COR on Wednesday reported second-quarter 2025 sales increased 10.3% to $75.5 billion, missing the consensus of $75.68 billion, primarily due to an 11.4% increase in revenue within the U.S. Healthcare Solutions segment.U.S. Healthcare Solutions revenue was $68.3 billion, due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class and specialty products to physician practices and health syste ...

Total revenues of €49.2 million compared to €32.8 million in the first quarter of 2024Cash and cash equivalents of €153.0 million at end of March 2025Further clinical and regulatory progress2025 financial outlook confirmed Saint-Herblain (France), May 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2025, provided key corporate updates and confirmed its 2025 financial guidance. The condensed co ...

Announcing New $250M Share Repurchase Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million; Adjusted EBITDA Increased 40% YOY to $162 million; GAAP Diluted EPS Increased 55% YOY to $0.93; non-GAAP Diluted EPS Increased 41% YOY to $1.111 Raising 2025 Financial Guidance Ranges for Total Revenue to $1,200 - $1,280 million, Representing YOY Growth of 18% - 26%, Adjusted EBITDA to $790 - $840 million, Representing YOY G ...

Core Insights - ONE Gas, Inc. reported strong financial results for the first quarter of 2025, with expectations to achieve the upper half of its previously announced financial guidance for the year [1][10] - The company declared a quarterly dividend of $0.67 per share, reflecting a commitment to returning value to shareholders [9] Financial Performance - Operating income for Q1 2025 was $180.5 million, up from $145.9 million in Q1 2024, driven by effective regulatory strategies and disciplined expense management [3][30] - Net income for the first quarter was $119.4 million, or $1.98 per diluted share, compared to $99.3 million, or $1.75 per diluted share, in the same period last year [9][20] - Total revenues increased to $935.2 million in Q1 2025 from $758.3 million in Q1 2024, with natural gas sales contributing significantly to this growth [30] Capital Expenditures and Investments - Capital expenditures and asset removal costs for Q1 2025 were $177.7 million, slightly down from $179.4 million in the same period last year, focusing on system integrity and service extension [4][30] - The company anticipates total capital investments of approximately $750 million for 2025, primarily for system integrity and replacement projects [10] Regulatory Activities - Kansas Gas Service submitted a request for a $7.2 million increase related to its Gas System Reliability Surcharge, with a decision expected by August 2025 [5] - Oklahoma Natural Gas filed for a $41.5 million base rate revenue increase, with a hearing scheduled for June 12, 2025 [6] Customer Metrics - The average number of customers increased to 2.305 million in Q1 2025, up from 2.290 million in Q1 2024, indicating growth in customer base across service areas [30][31] - The company experienced colder weather conditions, with actual degree days being 5% colder than normal, which positively impacted natural gas demand [9][31]

Coloplast revises financial guidance for FY 2024/25 and pre-announces H1 2024/25 key financial figures Coloplast revises the guidance on organic growth and EBIT margin before special items for FY 2024/25. The organic growth is now expected to be around 7%, from previously 8-9%. The EBIT margin before special items is now expected to be 27-28%, from previously around 28%. Key financial figures and developments in Q2: Group organic growth was 6% in Q2. The EBIT margin before special items was 27%.Organic gro ...

Core Insights - Ionis Pharmaceuticals reported a first-quarter EPS loss of 93 cents, an improvement from a loss of 98 cents, and better than the consensus estimate of a $1.12 loss [1] - Revenue for the first quarter of 2025 increased by 10% to $132 million, surpassing the consensus of $125.32 million, driven by higher commercial revenue [1] Financial Guidance - The company raised its 2025 revenue guidance by over 20% to a range of $725-$750 million, compared to previous guidance of over $600 million and the consensus of $659.37 million [4] - Ionis expects a 2025 adjusted operating loss of less than $375 million, improved from prior guidance of less than $495 million, with cash and equivalents projected at approximately $1.9 billion [4] Product Performance - The drug Tryngolza (olezarsen) generated over $6 million in net product sales in its first full quarter post-approval in the U.S. [6] - Wainua (eplontersen) for polyneuropathy generated $39 million in sales, resulting in $9 million in royalty revenue for the first quarter of 2025 [6] - Spinraza (nusinersen) for spinal muscular atrophy achieved global sales of $424 million, leading to $48 million in royalty revenue in the first quarter of 2025 [6]